Factor VIIa administration in traumatic brain injury: an AAST-MITC propensity score analysis

BACKGROUND: Recombinant factor VIIa (rFVIIa) has been used off-label as an adjunct in the reversal of warfarin therapy and management of hemorrhage after trauma. Only a handful of these reports are rigorous studies, from which results regarding safety and effectiveness have been mixed. There remains...

Descripción completa

Detalles Bibliográficos
Autores principales: Lombardo, Sarah, Millar, D, Jurkovich, Gregory J, Coimbra, Raul, Nirula, Ram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887758/
https://www.ncbi.nlm.nih.gov/pubmed/29766126
http://dx.doi.org/10.1136/tsaco-2017-000134

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887758/
https://www.ncbi.nlm.nih.gov/pubmed/29766126
http://dx.doi.org/10.1136/tsaco-2017-000134

Ejemplares similares